{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-027442","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.518076+00:00","generated_at":"2026-06-18T18:33:10.824090+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics regains Nasdaq minimum bid price compliance","bullets":["Received Nasdaq deficiency letter on Sept 12, 2022 for bid price below $1.00.","Regained compliance on March 1, 2023 after 10 consecutive trading days above $1.00 (Feb 14-28).","CEO Oren Gilad cited recent financing and progress on clinical asset ATRN-119 and pre-clinical ATRN-W1051."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-027442","json":"https://secwatch.observer/filing/0001104659-23-027442.json","markdown":"https://secwatch.observer/filing/0001104659-23-027442.md","text":"https://secwatch.observer/filing/0001104659-23-027442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923027442/0001104659-23-027442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923027442/tm238260d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:33:10.824090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}